18F-fluorodeoxyglucose | 68 |
18F-fluorothymidine | 68 |
Adjuvant | 98 |
Adjuvant treatments | 39 |
Adrenal cortex | 73 |
Adrenal invasion | 79 |
Adrenalectomy | 79 |
Alternative surgical approaches | 143 |
Angiomyolipoma | 76 |
Antopol-Goldman lesion | 150 |
Bacillus Calmette-Guérin | 120 |
Bacillus Calmette-Guérin failure | 63 |
Benign prostatic hyperplasia | 14 |
Bladder | 36 |
Bladder cancer | 18, 33, 63, 120, 127 |
Bladder tumour | 54 |
Bolu | 45 |
Clips | 124 |
Collecting system tumor | 150 |
Complication | 54 |
Conservative treatment | 143 |
CTLA-4 | 18 |
Current guidelines | 39 |
Cytoreductive nephrectomy | 26 |
Delay surgery | 133 |
Distal urethral leiomyoma | 153 |
Early detection | 94 |
Early stage | 39 |
Epigenomics | 138 |
Erectile dysfunction | 84 |
Estimated glomerular filtration rate | 127 |
Etiology | 45 |
Gallium-68 prostate-specific membrane antigen | 68 |
Genomics | 138 |
Gleason score | 1 |
Granulomatous prostatitis | 117 |
Hematuria | 150 |
High comorbidity | 14 |
Hormonal evaluation | 9 |
Hydronephrosis | 127 |
Immunotherapy | 18, 26 |
Incontinence | 84 |
Intracavitary | 120 |
Intravesical Bacillus Calmette-Guérin | 33 |
Intravesical salvage therapy | 63 |
Laparoscopic | 124 |
Laparoscopic adrenalectomy | 73 |
Leiomyoma | 153 |
Ligation | 124 |
Localized prostate cancer | 133 |
Lower urinary system symptoms | 89 |
Malignant melanoma | 36 |
Metastasectomy | 26 |
Metastases | 36 |
Metastatic prostate cancer | 105 |
Metastatic renal cancer | 26 |
Muscle uterine mass | 153 |
Neoadjuvant | 98 |
Nephrectomy | 124 |
Oligometastatic | 105 |
Oncocytic adrenocortical carcinoma | 73 |
Oncocytic neoplasm | 73 |
Oncologic survival | 143 |
PD-1 | 18 |
PD-L1 | 18 |
Positron emission tomography | 68 |
Postoperative renal function | 127 |
Prostate | 36 |
Prostate artery embolization | 14 |
Prostate biopsy | 1, 89, 133 |
Prostate cancer | 5, 9, 49, 59, 84, 94, 113 |
Prostate needle biopsy | 9 |
Prostate specific antigen | 49, 94, 113, 117 |
Prostate-specific antigen testing | 59 |
Prostatitis | 117 |
Quality of life | 84 |
Radical cystectomy | 127 |
Radical nephrectomy | 79 |
Radical orchiectomy | 39 |
Radical prostatectomy | 1, 105, 133 |
Radiotherapy | 105 |
Reactive arthritis | 33 |
Recurrence-free survival | 9 |
Renal cell carcinoma | 45, 68, 79, 98 |
Risk factors | 138 |
Robot-assisted laparoscopic radical prostatectomy | 84 |
Screening | 59, 94 |
Small cell carcinoma | 113 |
Stapler | 124 |
Strain | 120 |
Subcapsular orchiectomy | 5 |
Subepithelial pelvic hematoma | 150 |
Survival | 54, 105, 113 |
Targeted molecular therapy | 26 |
Targeted therapy | 98 |
Testicular germ cell tumors | 138 |
Testicular tumor | 39 |
Testosterone | 9 |
Total orchiectomy | 5 |
Transrectal ultrasound | 89 |
Tuberous sclerosis | 76 |
Tumor control | 143 |
Turkey | 49 |
Upper urinary system urothelial cancers | 143 |
Ureterocutaneostomy | 54 |
Urethra | 153 |
Urinary diversion | 54 |
Wunderlich syndrome | 76 |